title: Correlation of anti-inflammatory activity with peak tissue rather than peak plasma levels of BF389.
abstract: BF389 (Biofor 389) is a potent anti-inflammatory agent in various animal models including adjuvant and type II collagen arthritis in rats. In vitro assays indicate that this compound is a mixed inhibitor of arachidonic acid metabolism. The compound was evaluated for effects on the acute inflammatory response in the carrageenan paw edema assay in rats using a standard protocol in which the animals were given single or multiple (daily for 5 days) p.o. doses of the compound. Carrageenan was injected into the footpad of each animal 1 hr after dosing and volumes of both hind paws were determined 3 hr later. Basal serum prostaglandin (PG) E2 levels and PGE2 levels in arachidonate-stimulated blood from these same animals also were measured. No anti-inflammatory activity was observed in BF389-treated rats despite the occurrence of profound suppression of basal and stimulated PGE2 production. Animals treated with conventional nonsteroidal anti-inflammatory drugs in this assay had both suppressed PGE2 production and significant anti-inflammatory activity. In another study, groups of rats were given p.o. doses of 1, 10, 100 or 250 mg/kg of BF389 for 5 days in order to determine peak concentrations, T1/2s and total areas under the plasma (tissue) drug concentration curves in plasma and paws. Peak plasma concentrations occurred 2 to 4 hr postdosing and the half-life was 8 to 15 hr over the 1- to 250-mg/kg/day dose range. Peak paw concentrations occurred 6 to 12 hr postdosing and the levels were 9- to 14-fold greater in the paw than in the plasma.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, Indiana.
authors.forename: A M
authors.initials: AM
authors.lastname: Bendele
authors.forename: K J
authors.initials: KJ
authors.lastname: Ruterbories
authors.forename: S M
authors.initials: SM
authors.lastname: Spaethe
authors.forename: D N
authors.initials: DN
authors.lastname: Benslay
authors.forename: T D
authors.initials: TD
authors.lastname: Lindstrom
authors.forename: S J
authors.initials: SJ
authors.lastname: Lee
authors.forename: R W
authors.initials: RW
authors.lastname: Naismith
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000097:blood / Q000493:pharmacokinetics / Q000494:pharmacology*; D015232:Dinoprostone / Q000096:biosynthesis; D004487:Edema / Q000517:prevention & control; D006207:Half-Life; D008297:Male; D010078:Oxazines / Q000097:blood / Q000493:pharmacokinetics / Q000494:pharmacology*; D010636:Phenols / Q000097:blood / Q000493:pharmacokinetics / Q000494:pharmacology*; D051381:Rats; D011916:Rats, Inbred F344; D011917:Rats, Inbred Lew
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D010078:Oxazines; D010636:Phenols; C072260:Biofor 389; D015232:Dinoprostone